CredoScientia - Bibliothèque

Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma.

Pancreatic cancer remains a highly malignant and challenging tumor with a dismal 5-year survival rate of only 13%. The majority of patients are diagnosed at advanced stages, where surgical options are…

Thérapies de Conversion

Liu, H., Wang, Y., Zhang, Q., & Ke, N. (2024). Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma.. Front Oncol, 14, 1458517. https://doi.org/10.3389/fonc.2024.1458517

01/01/2024 Lire →

Analysis of the therapeutic effect and influencing factors on unresectable gastric cancer treated with conversion therapy.

BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death in China, and with the extensive development of conversion therapy, the treatment of advanced unresectable gastric …

Thérapies de Conversion

Han, S., Han, S., Qian, J., Guo, M., & Fan, J. (2024). Analysis of the therapeutic effect and influencing factors on unresectable gastric cancer treated with conversion therapy.. Front Oncol, 14, 1435398. https://doi.org/10.3389/fonc.2024.1435398

01/01/2024 Lire →

Case report: The impact of dissociated response of immunotherapy on the treatment strategy of advanced head and neck cancer.

Some special therapeutic responses may appear during immunotherapy, such as hyperprogression, pseudoprogression and so on. Dissociated response of immunotherapy has been clinically reported in recent …

Thérapies de Conversion

Jiang, S., Li, X., & Li, J. (2024). Case report: The impact of dissociated response of immunotherapy on the treatment strategy of advanced head and neck cancer.. Front Immunol, 15, 1460480. https://doi.org/10.3389/fimmu.2024.1460480

01/01/2024 Lire →

Surgical Treatment After Conversion Therapy in a Patient With Massive Hepatocellular Carcinoma.

Thérapies de Conversion

Fu, M. . M. . L., Jiang, M. . M. . J., Liu, M. . M. . M., Li, M. . M. . J., & Zhu, M. . D. . H. (2024). Surgical Treatment After Conversion Therapy in a Patient With Massive Hepatocellular Carcinoma.. Gastroenterol Nurs, 47(3), 222-228. https://doi.org/10.1097/SGA.0000000000000770

01/01/2024 Lire →

Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.

BACKGROUND: LCP-Tacro [LCPT], a novel once-daily, extended-release formulation of tacrolimus, has a reduced C with comparable AUC exposure, requiring a ∼30% dose reduction in contrast to immediate-rel…

Thérapies de Conversion

Anft, M., Zgoura, P., Skrzypczyk, S., Dürr, M., Viebahn, R., Westhoff, T. H., Stervbo, U., & Babel, N. (2024). Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.. Front Transplant, 3, 1405070. https://doi.org/10.3389/frtra.2024.1405070

01/01/2024 Lire →

Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study.

BACKGROUND: This study aimed to assess the effect of adjuvant therapy with different durations in patients with initially unresectable hepatocellular carcinoma (uHCC) after conversion surgery.METHODS:…

Thérapies de Conversion

Lin, Z. T., Wei, S. M., Wu, J. Y., Zhang, Z. B., Wang, S. J., Zhou, J. Y., Luo, M. C., Zeng, Z. X., Ou, X. Y., Fu, Y. K., Li, H., Liu, D. Y., Wu, J. Y., & Yan, M. L. (2024). Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study.. J Hepatocell Carcinoma, 11, 1777-1787. https://doi.org/10.2147/JHC.S477019

01/01/2024 Lire →

Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.

PURPOSE: Intra-arterial conversion therapy (ICT) is a promising option for patients with unresectable hepatocellular carcinoma (uHCC). However, the selection of sequential therapeutic modalities is st…

Thérapies de Conversion

Du, Y., An, C., & Liu, W. (2024). Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.. Int J Hyperthermia, 41(1), 2380001. https://doi.org/10.1080/02656736.2024.2380001

01/01/2024 Lire →

Comparison of immunochemotherapy and chemotherapy alone in conversion therapy for locally advanced unresectable esophageal squamous cell carcinoma.

BACKGROUND: The clinical value of preoperative immunochemotherapy and simple chemotherapy induction regimen in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinom…

Thérapies de Conversion

Xu, Z., You, Z., Chen, M., Zhang, M., Shen, C., Xu, D., Xu, K., & Tian, W. (2024). Comparison of immunochemotherapy and chemotherapy alone in conversion therapy for locally advanced unresectable esophageal squamous cell carcinoma.. Front Oncol, 14, 1370353. https://doi.org/10.3389/fonc.2024.1370353

01/01/2024 Lire →

Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.

Hepatocellular carcinoma (HCC) ranks as the sixth most common malignancy globally, with the majority of patients presenting at the initial diagnosis with locally advanced or metastatic disease, preclu…

Thérapies de Conversion

Ai, H., Gong, T., Ma, Y., Ma, G., Ding, W., Ding, W., Wang, W., & Zhao, X. (2024). Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.. Front Immunol, 15, 1358602. https://doi.org/10.3389/fimmu.2024.1358602

01/01/2024 Lire →

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.

PURPOSE: To explore the efficacy and safety of FOLFOXIRI plus cetuximab regimen as conversion therapy for patients with unresectable RAS/BRAF wild-type colorectal liver-limited metastases (CLM).PATIEN…

Thérapies de Conversion

Yang, W., Chen, D., Niu, Y., Wu, G., Huang, Z., Bi, X., Zhao, H., Che, X., & Sun, Y. (2024). FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.. Front Oncol, 14, 1375906. https://doi.org/10.3389/fonc.2024.1375906

01/01/2024 Lire →

Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy.

PURPOSE: The aim of this study was to investigate the efficacy and safety of conversion surgery for advanced hepatocellular carcinoma (HCC) after hepatic arterial infusion chemotherapy (HAIC).PATIENTS…

Thérapies de Conversion

Li, W., Zheng, Z., Wang, J., Wu, T., Wang, J., Pan, Y., Chen, J., Hu, D., Xu, L., Zhang, Y., Chen, M., & Zhou, Z. (2024). Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy.. J Hepatocell Carcinoma, 11, 463-475. https://doi.org/10.2147/JHC.S447387

01/01/2024 Lire →

Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.

BACKGROUND: This study evaluates the efficacy of alpha-fetoprotein (AFP) response as a surrogate marker for determining recurrence-free survival (RFS) in patients with unresectable hepatocellular carc…

Thérapies de Conversion

Lin, K. Y., Zhang, J. X., Lin, Z. W., Chen, Q. J., Luo, L. P., Chen, J. H., Wang, K., Tai, S., Zhang, Z. B., Wang, S. F., Li, J. D., Wang, K., Zheng, L., Zheng, S. M., Wu, M. M., Lin, K. C., Yang, T., & Zeng, Y. Y. (2024). Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.. Front Immunol, 15, 1308543. https://doi.org/10.3389/fimmu.2024.1308543

01/01/2024 Lire →